Arrowhead Pharmaceuticals (ARWR) Tax Provisions (2021 - 2026)

Arrowhead Pharmaceuticals (ARWR) has 6 years of Tax Provisions data on file, last reported at $7000.0 in Q1 2026.

• Quarterly Tax Provisions fell 99.6% year-over-year to $7000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.6 million (up 721.93% YoY) and the FY2025 annual result came in at $21.4 million, up 874.09% from the prior year.
• Tax Provisions fell to $7000.0 in Q1 2026, from $29000.0 in the prior quarter.
• In the past five years, Tax Provisions ranged from a high of $20.0 million in Q3 2025 to a low of -$3.3 million in Q4 2023.
• A 5-year average of $2.3 million and a median of $533000.0 in 2024 frame the typical range for Tax Provisions.
• Annual changes were most pronounced in 2022 — Tax Provisions jumped 189150.0% — and 2026, when it plunged 99.6%.
• Tracing ARWR's Tax Provisions over 5 years: stood at $3.8 million in 2022, then slumped by 187.53% to -$3.3 million in 2023, then surged by 103.11% to $103000.0 in 2024, then sank by 71.84% to $29000.0 in 2025, then plunged by 75.86% to $7000.0 in 2026.
• The last three Tax Provisions figures came in at $7000.0 (Q1 2026), $29000.0 (Q4 2025), and $20.0 million (Q3 2025), per Business Quant data.